Clinical Trial Detail

NCT ID NCT03765229
Title An Exploratory Study of Pembrolizumab Plus Entinostat in Non-Inflamed Stage III/IV Melanoma
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements no
Sponsors UNC Lineberger Comprehensive Cancer Center
Indications

melanoma

Therapies

Entinostat + Pembrolizumab

Age Groups: adult senior

No variant requirements are available.